Abstract Search

ea0022p659 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Study of pituitary function in acromegaloidism

Sierra Wilfredo Guanipa , Catalina Pablo Fernandez , Fernandez Concepcion Paramo , Garcia Elias Alvarez , Olivie Amalia Andrade , Pena Eduardo , Ferrer Federico Mallo

Acromegaloidism includes clinical features of acromegaly with GH and IGF1 normal levels at baseline and dynamic, without findings of extrapituitary or pituitary tumour. It has been associated with various conditions without a definite pattern. The aim was to evaluate whether there are differences in some hormonal pituitary axis from acromegaloid subjects with respect to acromegalic and healthy subjects. We designed a comparative, multicenter, casecontrol study in three h...

0 shares

ea0022p662 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Acromegaloidism: description of fifteen cases

Sierra Wilfredo Guanipa , Fernandez Concepcion Paramo , Catalina Pablo Fernandez , Garcia Elias Alvarez , Olivie Amalia Andrade , Pena Eduardo , Ferrer Federico Mallo

Acromegaloidism is a very rare entity (have been 54 cases reported worldwide) that presents with clinical acromegaly and normal somatotropic axis, without findings of pituitary or extrapituitary tumour. Its origin has not been clearly established, although it is associated with several pathophysiological conditions. The local ethics committee approved to perform an observational and multicenter study in three hospitals from a region with approximately 800 000 people over 18 ye...

0 shares

ea0032p902 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Efficacy and safety of lanreotide in combination with cabergoline in clinical practice in patients with active acromegaly with monotherapy failure

Vilchez Ricardo , Bernabeu Ignacio , Blanco Concepcion , Cordido Fernando , Paja Miguel , Casany Rosa , Fajardo Carmen , Maraver Silvia , Martin Tomas , Lucas Tomas , Arnes Juan Antonio Garcia , Catalina Pablo Fernandez , Icaya Maria Purificacion Martinez de , Sesmilo Gemma , Pico Antonio , Marazuela Monica , Soto Alfonso , Domingo Manuel Puig , on behalf of ACROCOMB study group

Introduction: ACROCOMB, a retrospective Spanish Multicenter study, evaluated the efficacy and safety of lanreotide (LAN) combined with cabergoline (CAB), or pegvisomant in patients with acromegaly.Methods: patients treated with LAN+CAB at 44 Spanish Endocrinology Departments were included.Results: 33% male patients, median age: 50.4 years. Mean time from diagnosis: 5.9±6.9 years. Tumour size at diagnosis: 21.9 mm. 83% of patie...

0 shares

Endocrine Abstracts

Study of pituitary function in acromegaloidism

Acromegaloidism: description of fifteen cases

Efficacy and safety of lanreotide in combination with cabergoline in clinical practice in patients with active acromegaly with monotherapy failure

BiosciAbstracts